FidoCure is the first and only service to offer cancer care with a dual-focus approach that benefits both dogs and humans. Leveraging the genetic similarities between human and canine cancers, FidoCure offers targeted therapies that allow for more effective treatments extending dog lives by up to 3x. Through our Next Generation DNA Sequencing Test, the first of its kind to introduce human-grade targeted treatments to our canine companions, we have assembled the worlds largest canine cancer genomics database which uses genomic testing to provide veterinarians with critical data, enabling them to tailor the most effective targeted therapies for each individual dog patient. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports.
FidoCure is proud to be leading precision medical research in canine oncology, and our team is committed to revolutionizing the way cancer care is delivered to dogs and humans alike. Our technology provides advanced diagnostics and facilitates access to precision medicines at the touch of a button.
FidoCure by the One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Our vision along with our stakeholders, is a world free of cancer achieved by cost-effective, personalized precision medicine for both humans and their canine companions.
Learn more at www.fidocure.com.
